Aduhelm - Alzheimer's Amyloid Plaque Tests - First Choice Neurology - Jeffrey Gelblum, MD

Dr. Jeff Gelblum, Senior Neurologist with First Choice Neurology talks about diagnostic tests used to help diagnose Alzheimer’s disease, the prelude to the treatment of Aduhelm. Biogen’s Aduhelm (Aducanumab) was recently FDA approved as a promising infusion treatment for Alzheimer’s patients. Aduhelm is the first new treatment approved for Alzheimer’s since 2003 and is the first therapy that targets the fundamental pathophysiology of the disease. Researchers evaluated Aduhelm’s efficacy in three separate studies. Patients receiving the treatment had a significant reduction of amyloid plaque, while patients in the control arm of the studies had no reduction of amyloid plaque. Dr. Gelblum asserts, “the new ABC’s of Alzheimer’s treatment are: Assessment of clinical status; Beta-amyloid in the CSF; Consider infusion of Aduhelm (Aducanumab)”. For additional information about Alzheimer's disease, visit https://www.fcneurology.net/ #aduhelm #amyloidplaque #alzheimersdisease